Effect of Nicotine on Brain Reward Pathways
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Belmont, Massachusetts, United States, 02478
- Mclean Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria for subjects with Major Depressive Disorder:
- Provide written informed consent;
- Both genders and all ethnic origins, age between 18 and 45;
- Meet DSM-IV diagnostic criteria for MDD (diagnosed with the use of the SCID);
- A baseline HAM-D score of 16 or greater;
- Absence of pregnancy;
Absence of any psychotropic medication for at least 2 weeks:
- 6 weeks for fluoxetine
- 6 months for neuroleptics
- 2 weeks for benzodiazepines
- 2 weeks for any other antidepressants
Inclusion Criteria for Healthy Controls
- Absence of medical, neurological, and psychiatric illness (including alcohol and substance abuse); as assessed by subject history and a structured clinical interview (SCID);
- Provide written informed consent;
- Both genders and all ethnic origins, age between 18 and 45;
- Absence of any medications for at least 3 weeks;
- Absence of pregnancy.
Exclusion Criteria:
- Subjects with suicidal ideation where outpatient treatment is determined unsafe. These patients will be immediately referred to a licensed psychologist or psychiatrist to determine the appropriate clinical treatment;
- Serious or unstable medical illness
- Lifetime history of seizure disorder;
- Lifetime history or current diagnosis of any of the following DSM-IV psychiatric illnesses: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, ADHD, patients with mood congruent or mood incongruent psychotic features; simple phobia, social anxiety disorder and generalized anxiety disorders will be allowed only if secondary to MDD;
- Patients with a lifetime history of electroconvulsive therapy (ECT);
- Failure to meet standard MRI safety requirements;
- May not have used any nicotine product in the past year; must report fewer than 20 lifetime uses of nicotine
- Must have an expired carbon monoxide level of less than or equal to 10 ppm.
- Use of anticholinergic drugs in the past week
- Any past or present history of cardiac problems including known arrhythmias, acute coronary syndrome, or ischemic heart disease
- Uncontrolled hypertension
- History of substance abuse in the past 6 months (other than caffeine), self-reported use of marijuana in past month, or history of treatment with methadone
- Heavy caffeine users (consume greater than 500 mg on a regular or daily basis)
- Subjects that cannot speak English
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Placebo comparator
|
Single Acute dose
Other Names:
|
|
Experimental: Nicotine
2mg of nicotine in the form of a nicotine polacrilex lozenge will be administered orally, one time. 4mg of nicotine in the form of a nicotine polacrilex lozenge will be administered orally, one time. |
Single Acute dose
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Placebo in functional magnetic resonance imaging (fMRI) BOLD Response
Time Frame: Participants will be assessed during 2 fMRI scanning sessions, an expected average of 2 weeks.
|
Nicotine will enhance the fMRI BOLD response to monetary reinforcers relative to placebo administration
|
Participants will be assessed during 2 fMRI scanning sessions, an expected average of 2 weeks.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Amy Janes, Ph.D, Mclean Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2014P002495-01
- 5K01DA029645-04 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.